Cervical Cancer

Cervical cancer surgery can often result in irreversible damage to the pelvic nerves. This study, published in the European Journal of Nuclear Medicine and Molecular Imaging, examines the feasibility and safety of intraoperative near-infrared fluorescence imaging (NIR-FI) with indocyanine green in identifying pelvic nerves during radical hysterectomy for cervical cancer. A total of 66 patients with cervical...

Total mesometrial resection (TMMR) and therapeutic lymphadenectomy (tLNE) are two surgical interventions used to treat early cervical cancer. They are both based on the ontogenic cancer field model and have exhibited good locoregional control rates without adjuvant chemoradiation in a unicentric setting. This study, published in the Journal of Gynecologic Oncology, sought to provide prospective, multicentric...

Treatment for advanced cervical cancer is limited, but the therapeutic HPV vaccine shows promise as a possible treatment option. In this study, published in Biomaterials, researchers constructed a novel HPV nanovaccine and tested its ability to inhibit cervical cancer progression in mice. This HPV vaccine therapy is novel because it combines nanotechnology and photodynamic therapy, which...

Recent findings have shown that neuropeptide substance P (SP) regulates many tumor-related processes via the neurokinin-1 receptor (NK1R). This study, published in Molecular Biology Reports, used HeLa cells to analyze the relevance of the SP/NK1R system in the pathogenesis and treatment of cervical cancer.  Ultimately, it was found that SP increased HeLa cell proliferation while treatment...

Observational studies have shown a reduction in invasive cervical cancer incidence and mortality thanks to screening programs that use cervical cytological testing. Moreover, randomized controlled trials have shown that cytological testing plus hrHPV testing (co-testing) further reduces invasive cervical cancer incidence.  The current guidelines recommend three main screening options: cytological testing, standalone hrHPV testing, and...

Cervical cancer screening over age 65 is limited. However, this demographic continues to experience a steady cervical cancer incidence and a worse prognosis.  This study, published in Gynecologic Oncology, sought to examine cervical cancer characteristics among women older than 65, including disease, treatment, and survival data, to determine if there is a need to update current cervical cancer...

It is well-known that people who belong to sexual minority groups may face increased risk factors for cancer while simultaneously being less likely to participate in screening. This study, published in Cancer Epidemiology, Biomarkers & Prevention, examined the relationship among sexual minority status, race/ethnicity, and cervical cancer screening rates. The researchers utilized data from the...

Papanicolaou (Pap) test is an effective method for cervical cancer screening. This study, published in the European Journal of Cancer Care, assessed the barriers South Asian women in Hong Kong face in obtaining cervical cancer screening.  A total of 776 women 21 and older with no prior history of cervical cancer or hysterectomy participated in this cross-sectional...

The human papillomavirus (HPV) is the most common risk factor for developing cervical cancer. Vaccines and early screening can prevent cervical cancer from developing. This study, published in the International Journal of Environmental Research and Public Health, sought to assess cervical cancer knowledge and cervical cancer prevention and screening practices among Saudi women living in Al Madinah...